blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3122356

EP3122356 - TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION [Right-click to bookmark this link]
Former [2017/05]TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES
[2019/51]
StatusNo opposition filed within time limit
Status updated on  09.04.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  01.05.2020
FormerGrant of patent is intended
Status updated on  15.12.2019
FormerExamination is in progress
Status updated on  26.06.2019
FormerRequest for examination was made
Status updated on  30.12.2016
FormerThe international publication has been made
Status updated on  09.11.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Dalhousie University
1344 Summer Street Suite 207
Halifax, Nova Scotia B3H 4R2 / CA
[2020/23]
Former [2017/05]For all designated states
Dalhousie University
1344 Summer Street Suite 207
Halifax, Nova Scotia B3H 4R2 / CA
Inventor(s)01 / ROBERGE, Michel
1344 Summer Street
Suite 207
Halifax, Nova Scotia B3H 4R2 / CA
02 / MCMASTER, Chris
1344 Summer Street
Suite 207
Halifax, Nova Scotia B3H 4R2 / CA
03 / ZIMMERMAN, Carla
1344 Summer Street
Suite 207
Halifax, Nova Scotia B3H 4R2 / CA
04 / POON, Pak
1344 Summer Street
Suite 207
Halifax, Nova Scotia B3H 4R2 / CA
 [2017/05]
Representative(s)Barton, Russell Glen
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[N/P]
Former [2020/23]Barton, Russell Glen
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Former [2017/05]Barton, Russell Glen
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Application number, filing date15776221.210.04.2015
[2017/05]
WO2015CA50295
Priority number, dateUS201461978091P10.04.2014         Original published format: US 201461978091 P
[2017/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015154191
Date:15.10.2015
Language:EN
[2015/41]
Type: A1 Application with search report 
No.:EP3122356
Date:01.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 15.10.2015 takes the place of the publication of the European patent application.
[2017/05]
Type: B1 Patent specification 
No.:EP3122356
Date:03.06.2020
Language:EN
[2020/23]
Search report(s)International search report - published on:CA15.10.2015
(Supplementary) European search report - dispatched on:EP11.09.2017
ClassificationIPC:A61K31/4425, A61P25/16
[2019/51]
CPC:
A61K31/495 (EP,US); A61K31/381 (EP,US); A61K31/4402 (EP,US);
A61K31/4425 (EP,US); A61K31/496 (EP,US); A61P25/16 (EP);
A61P43/00 (EP); C07D213/61 (EP,US); C07D213/74 (EP,US);
C07D295/073 (EP,US) (-)
Former IPC [2017/41]A61K31/4402, A61K31/381, A61P25/16, C07D213/61, A61K31/4425, C07D213/74, A61K31/495, A61K31/496, C07D295/073
Former IPC [2017/05]A61K31/4402, A61K31/381, A61P25/16, C07D213/61, C07D295/135
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/05]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:BEHANDLUNG VON MORBUS PARKINSON DURCH ARFGAP1-HEMMUNG[2019/51]
English:TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION[2019/51]
French:TRAITEMENT DE LA MALADIE DE PARKINSON PAR INHIBITION D'ARFGAP1[2019/51]
Former [2017/05]BEHANDLUNG VON MORBUS PARKINSON DURCH ARFGAP1-HEMMUNG MIT SUBSTITUIERTEN PIPERAZINDERIVATEN
Former [2017/05]TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES
Former [2017/05]TRAITEMENT DE LA MALADIE DE PARKINSON PAR INHIBITION D'ARFGAP1 EN UTILISANT DES DÉRIVÉS DE PIPÉRAZINE SUBSTITUÉS
Entry into regional phase25.10.2016National basic fee paid 
25.10.2016Search fee paid 
25.10.2016Designation fee(s) paid 
25.10.2016Examination fee paid 
Examination procedure25.10.2016Examination requested  [2017/05]
25.10.2016Date on which the examining division has become responsible
26.03.2018Amendment by applicant (claims and/or description)
01.07.2019Despatch of a communication from the examining division (Time limit: M04)
02.10.2019Reply to a communication from the examining division
16.12.2019Communication of intention to grant the patent
17.04.2020Fee for grant paid
17.04.2020Fee for publishing/printing paid
17.04.2020Receipt of the translation of the claim(s)
Opposition(s)04.03.2021No opposition filed within time limit [2021/19]
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
27.04.2018Renewal fee patent year 04
29.04.2019Renewal fee patent year 05
27.04.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.04.2015
AL03.06.2020
AT03.06.2020
CY03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
MK03.06.2020
MT03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
TR03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
[2024/41]
Former [2024/29]HU10.04.2015
AL03.06.2020
AT03.06.2020
CY03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
MK03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
TR03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2024/22]HU10.04.2015
AL03.06.2020
AT03.06.2020
CY03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
MK03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2023/30]HU10.04.2015
AL03.06.2020
AT03.06.2020
CY03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2023/29]HU10.04.2015
AL03.06.2020
AT03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2022/23]AL03.06.2020
AT03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2022/10]AL03.06.2020
AT03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
PT06.10.2020
Former [2021/50]AL03.06.2020
AT03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
MC03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2021/24]AL03.06.2020
AT03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SI03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2021/21]AL03.06.2020
AT03.06.2020
CZ03.06.2020
DK03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2021/10]AL03.06.2020
AT03.06.2020
CZ03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
NL03.06.2020
PL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SK03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
IS03.10.2020
PT06.10.2020
Former [2021/09]AL03.06.2020
AT03.06.2020
CZ03.06.2020
EE03.06.2020
ES03.06.2020
FI03.06.2020
HR03.06.2020
IT03.06.2020
LT03.06.2020
LV03.06.2020
NL03.06.2020
RO03.06.2020
RS03.06.2020
SE03.06.2020
SM03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
PT06.10.2020
Former [2021/04]AL03.06.2020
FI03.06.2020
HR03.06.2020
LT03.06.2020
LV03.06.2020
NL03.06.2020
RS03.06.2020
SE03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
Former [2021/01]FI03.06.2020
HR03.06.2020
LT03.06.2020
LV03.06.2020
RS03.06.2020
SE03.06.2020
BG03.09.2020
NO03.09.2020
GR04.09.2020
Former [2020/51]FI03.06.2020
HR03.06.2020
LT03.06.2020
LV03.06.2020
RS03.06.2020
SE03.06.2020
NO03.09.2020
GR04.09.2020
Former [2020/50]FI03.06.2020
HR03.06.2020
LT03.06.2020
LV03.06.2020
SE03.06.2020
NO03.09.2020
GR04.09.2020
Former [2020/48]FI03.06.2020
LT03.06.2020
SE03.06.2020
NO03.09.2020
Former [2020/47]LT03.06.2020
NO03.09.2020
Documents cited:Search[A]WO2012162254  (ELAN PHARM INC [US], et al) [A] 1-3 * page 4, paragraph 10 - page 5, paragraph 11 * * page 27, paragraph 48 * * claim 1 *;
 [A]  - STAFA KLODJAN ET AL, "GTPase Activity and Neuronal Toxicity of Parkinson's Disease-Associated LRRK2 Is Regulated by ArfGAP1", PLOS GENETICS, (201202), vol. 8, no. 2, XP002772924 [A] 1-3 * abstract *

DOI:   http://dx.doi.org/10.1371/journal.pgen.1002526
International search[X]WO9728128  (ZENECA LTD [GB], et al) [X] 9 *example 20; example 42*;
 [XY]CA2540186  (VERTEX PHARMA [US]) [X] 1, 2, 5, 8, 9, 13 *page 38, compound 1; page 39, compound 18; examples; claim 53* [Y] 3, 4, 6, 7, 12;
 [XY]CA2568524  (VERTEX PHARMA [US]) [X] 1, 2, 8, 9 *claim 42; page 60, compound at line 17* [Y] 3, 4, 6, 7, 12;
 [X]CA2652449  (WARATAH PHARMACEUTICALS INC [CA]) [X] 9 *page 144, first entry*;
 [X]CA2687790  (F2G LTD [GB]) [X] 9 *reference example 40*;
 [X]CA2690299  (HOFFMANN LA ROCHE [CH]) [X] 1, 8 *abstract; table 2; claims 16 and 17*;
 [X]CA2725445  (F2G LTD [GB]) [X] 9, 11 *page 117, example 78*;
 [X]CA2809557  (MEDICAL RES COUNCIL TECHNOLOGY [GB], et al) [X] 1, 8 *page 1, lines 3-6; page 26, compounds 13 and 14*;
 [X]CA2827648  (ABBVIE INC [US]) [X] 9, 11 *example 247A*;
 [XY]WO2013033037  (UNIV CALIFORNIA [US], et al) [X] 1, 2, 8, 9, 11 *page 296, entry #6 (IND-0018629); claims 45-49, 104* [Y] 3, 4, 6, 7, 12;
 [X]  - LEE, B. D. et al., "Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease", Nature Medicine, (20100000), vol. 16, pages 998 - 1000, XP055230314 [X] 1, 8 * + supplementary material page 15 *abstract; table 1.1, entry 4*

DOI:   http://dx.doi.org/10.1038/nm.2199
 [X]  - FEENSTRA, R. et al., "SLV308", Drugs of the Future, (20010000), vol. 26, no. 2, pages 128 - 132, XP055230320 [X] 1, 8 *abstract*

DOI:   http://dx.doi.org/10.1358/dof.2001.026.02.608830
 [X]  - DUNCAN, M. C. et al., "Composite synthetic lethal identification of membrane traffic inhibitors", PNAS, (20070000), vol. 104, no. 15, pages 6235 - 6240, XP055230322 [X] 9, 11 *compounds 5353860, A5, S8 and S9*

DOI:   http://dx.doi.org/10.1073/pnas.0607773104
 [X]  - LI, Z. et al., "Discovery and Preliminary Structure-Activity Relationship of Arylpiperazines as Novel, Brain-Penetrant Antiprion Compounds", Medicinal Chemistry Letters, (20130000), vol. 4, pages 397 - 401, XP055230326 [X] 9, 11 *compounds 7 and 13*

DOI:   http://dx.doi.org/10.1021/ml300472n
 [X]  - FAUL, M. M. et al., "Green Chemistry Approach to the Synthesis of N-Substituted Piperidones", JOC, (20030000), vol. 68, pages 5739 - 5741, XP055230328 [X] 9, 11 *compound 12*

DOI:   http://dx.doi.org/10.1021/jo026848i
 [X]  - CHEMICAL ABSTRACTS, Database accession no. 915879-01-5 [X] 9, 14
 [X]  - CHEMICAL ABSTRACTS, Database accession no. 296792-87-5 [X] 9, 15
 [X]  - BAHNER, C. T. et al., "Qutemary Salts of Halogenated Pyridines and Quinolines", JACS, (19510000), vol. 73, pages 3499 - 3501, XP055230331 [X] 10 *table 1, entry 13*

DOI:   http://dx.doi.org/10.1021/ja01151a501
by applicantCA2809557
 WO2012162254
    - LEE, B. D. et al., Nature medicine
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.